JP2018537988A - 標的核酸のループ介在等温増幅(lamp)の蛍光検出の方法、オリゴヌクレオチド及びそれらのキット - Google Patents
標的核酸のループ介在等温増幅(lamp)の蛍光検出の方法、オリゴヌクレオチド及びそれらのキット Download PDFInfo
- Publication number
- JP2018537988A JP2018537988A JP2018532236A JP2018532236A JP2018537988A JP 2018537988 A JP2018537988 A JP 2018537988A JP 2018532236 A JP2018532236 A JP 2018532236A JP 2018532236 A JP2018532236 A JP 2018532236A JP 2018537988 A JP2018537988 A JP 2018537988A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- target nucleic
- primer
- loop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 89
- 238000000034 method Methods 0.000 title claims abstract description 54
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 29
- 238000007397 LAMP assay Methods 0.000 title claims description 95
- 108020004707 nucleic acids Proteins 0.000 title claims description 26
- 102000039446 nucleic acids Human genes 0.000 title claims description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 60
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 39
- 230000003321 amplification Effects 0.000 claims abstract description 38
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 27
- 239000002853 nucleic acid probe Substances 0.000 claims description 27
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 19
- 239000000523 sample Substances 0.000 claims description 16
- 230000000295 complement effect Effects 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 11
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 10
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 10
- 230000005284 excitation Effects 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 238000006073 displacement reaction Methods 0.000 claims description 7
- 241000237502 Ostreidae Species 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 235000020636 oyster Nutrition 0.000 claims description 5
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 3
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims description 3
- 102000004594 DNA Polymerase I Human genes 0.000 claims description 2
- 108010017826 DNA Polymerase I Proteins 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 claims description 2
- 230000005945 translocation Effects 0.000 claims 1
- 230000007246 mechanism Effects 0.000 abstract description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000013615 primer Substances 0.000 description 71
- 238000006243 chemical reaction Methods 0.000 description 26
- 238000003556 assay Methods 0.000 description 22
- 238000001514 detection method Methods 0.000 description 22
- 238000001327 Förster resonance energy transfer Methods 0.000 description 21
- 239000000975 dye Substances 0.000 description 19
- 238000009830 intercalation Methods 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 239000000047 product Substances 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 7
- 241000696962 White spot syndrome virus Species 0.000 description 6
- 235000011180 diphosphates Nutrition 0.000 description 6
- 239000013067 intermediate product Substances 0.000 description 6
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 5
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 5
- 238000012417 linear regression Methods 0.000 description 5
- 230000006820 DNA synthesis Effects 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 3
- 238000010835 comparative analysis Methods 0.000 description 3
- 229910001437 manganese ion Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229960002378 oftasceine Drugs 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 101001000104 Homo sapiens Myosin-11 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 101150054386 Myh11 gene Proteins 0.000 description 2
- 102100036639 Myosin-11 Human genes 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- XZTWHWHGBBCSMX-UHFFFAOYSA-J dimagnesium;phosphonato phosphate Chemical compound [Mg+2].[Mg+2].[O-]P([O-])(=O)OP([O-])([O-])=O XZTWHWHGBBCSMX-UHFFFAOYSA-J 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000000295 emission spectrum Methods 0.000 description 2
- 230000005281 excited state Effects 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FTBBGQKRYUTLMP-UHFFFAOYSA-N 2-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C1=CC=CN1 FTBBGQKRYUTLMP-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 1
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 241000318927 Shrimp white spot syndrome virus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000011901 isothermal amplification Methods 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical group OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- -1 pyrophosphate ions Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/161—Modifications characterised by incorporating target specific and non-target specific sites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/30—Oligonucleotides characterised by their secondary structure
- C12Q2525/301—Hairpin oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2527/00—Reactions demanding special reaction conditions
- C12Q2527/101—Temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/119—Strand displacement amplification [SDA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/10—Detection mode being characterised by the assay principle
- C12Q2565/101—Interaction between at least two labels
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
実験セクション
例1−本発明のLAMP法とChouらのLAMPアッセイとの比較
試料調製
Chouらに記載のLAMPアッセイと本発明のLAMP法とを比較するために、好適な標的核酸配列を調製した。要約すると、Sfi I/Sfi I制限部位の組合せを用いて、pMA−Tベクター(GENEART)に、白斑症候群ウイルス(WSSV)ゲノム(nt226681−227934、GenBank AF332093.1)由来の350bpのDNA断片をクローニングして、陽性対照を得た。組換えWSSVプラスミドについて、約2×106コピー/μL〜2×101コピー/μLの範囲の10倍希釈系列を調製した。
比較分析に用いたLAMPオリゴヌクレオチドプライマー及びプローブをChouらに記載されているように設計し、以下の表1に列挙する。
1)1つの単一の核酸プローブ、すなわち、その3’末端がフルオレセインにより標識されているLCFを含有し、
2)ループプライマーLoopBを含まず、後者は、その5’末端が蛍光部分LC640により標識されたLCQプライマーに置換される。上記に照らして、Chouらによる方法は、標識されたドナープローブと標識されたアクセプタープローブとの間のFRET機構による蛍光増幅シグナルの生成を提供する。逆に、本発明による方法では、アクセプターオリゴヌクレオチドの機能は、予め標識されたループプライマーの1つによって行われ、それによってLAMP反応に用いられるオリゴヌクレオチドの数が減少する。さらに、本発明の方法は、同じ標的ヌクレオチド配列への結合に関して、前記アッセイに使用されるFRETプローブと、ループプライマーとが競合する可能性があるというChouらによるアッセイに伴う欠点を克服する。
Microsoft Excel内の統計パッケージを使用してデータ分析を行った。同じパッケージを線形回帰分析に使用した。
試料調製
インターカレーティング色素の使用を含むLAMPアッセイと本発明の方法の性能を比較するために、好適な標的核酸配列を調製した。要約すると、Sfi I/Sfi I制限部位の組合せを用いて、pMA−Tベクター(GENEART)に、MYH11遺伝子(GenBank D10667.1)由来の350bpのDNA断片をクローニングして、陽性対照を得た。
以下の表2に、比較分析に使用されたLAMPオリゴヌクレオチドプライマー及びプローブを列挙する。
Microsoft Excel内の統計パッケージを使用してデータ分析を行った。同じパッケージを線形回帰分析に使用した。
Claims (9)
- 標的核酸配列のループ介在等温増幅(LAMP)を検出する方法であって、該方法が、
i)前記標的核酸配列を含有する可能性がある試験試料と、鎖置換活性ならびに以下のa、b、c及びdからなるオリゴヌクレオチドのセットを有するDNAポリメラーゼとを接触させる工程;
a.第1のアウタープライマーF3及び第2のアウタープライマーB3、
b.第1のインナープライマーFIP及び第2のインナープライマーBIP、
(ここで、FIPは3’核酸配列F2及び5’核酸配列F1cからなり、BIPは3’核酸配列B2及び5’核酸配列B1cからなり、
F2は前記標的核酸配列のF2c領域に相補的であり、B2は前記標的核酸配列のB2c領域に相補的であり、
F2c及びB2cは、前記標的核酸配列の反対側の鎖上に位置する非重複領域である。)
c.前記標的核酸配列のそれぞれの領域にハイブリダイズすることができる第1のループプライマーLF及び場合により第2のループプライマーLB、
(ここで前記ループプライマーLF又は存在する場合前記ループプライマーLBのいずれかは、その5’末端が少なくとも1つのアクセプターフルオロフォアにより標識されている。)
d.前記標識されたLF又はLBループプライマーに対して5’の位置で前記標的核酸配列にハイブリダイズすることができ、その結果、核酸プローブが前記標的核酸配列にハイブリダイズした際に、前記標識されたLF又はLBループプライマーの前記5’末端に、前記核酸プローブの前記3’末端を近接させる1つの核酸プローブ
(ここで前記核酸プローブは、前記LF又はLBループプライマーの前記少なくとも1つのアクセプターフルオロフォアに励起エネルギーを伝達することができる少なくとも1つのドナーフルオロフォアにより、その3’末端が標識され、前記アクセプターフルオロフォアの蛍光発光の強度が前記ドナーフルオロフォア励起エネルギーの吸収時に増加する。)、並びに
ii)前記標的核酸配列のLAMP増幅の指標として蛍光パラメーターの変化を検出する工程を含み、前記蛍光パラメーターの前記変化は前記アクセプターフルオロフォアの前記蛍光発光の強度の増加である、上記方法。 - 前記核酸プローブの前記3’末端が、前記標的核酸配列にハイブリダイズした際に、前記標識されたLF又はLBループプライマーの前記5’末端から6ヌクレオチド以下、好ましくは1ヌクレオチド以下、さらに好ましくは0ヌクレオチド離れている、請求項1に記載の方法。
- 前記標識されたLF又はLBループプライマーが、i)前記標的核酸配列の前記それぞれの領域を選択的に認識及びハイブリダイズすることができる中心ループ配列、並びにii)二本鎖ステムを形成するように互いに相補的である5’末端配列及び3’末端配列を含むステムループ伸長可能プライマーである、請求項1又は2に記載の方法。
- 前記標的核酸配列が、好ましくは点変異、欠失、挿入又は転座から選択される少なくとも1つの変異を含む、請求項1〜3のいずれか一項に記載の方法。
- 前記標的核酸配列の増幅が、前記少なくとも1つの変異の存在又は非存在を示す、請求項4に記載の方法。
- 標的核酸配列のループ介在等温増幅(LAMP)を検出するためのオリゴヌクレオチドのセットであって、前記セットが、
a.第1のアウタープライマーF3及び第2のアウタープライマーB3、
b.第1のインナープライマーFIP及び第2のインナープライマーBIP、
(ここでFIPは3’核酸配列F2及び5’核酸配列F1cからなり、BIPは3’核酸配列B2及び5’核酸配列B1cからなり、
F2は前記標的核酸配列のF2c領域に相補的であり、B2は前記標的核酸配列のB2c領域に相補的であり、
F2c及びB2cは、前記標的核酸配列の反対側の鎖上に位置する非重複領域である。)
c.前記標的核酸配列のそれぞれの領域にハイブリダイズすることができる第1のループプライマーLF及び場合により第2のループプライマーLB、
(ここで前記LFループプライマー又は存在する場合前記LBループプライマーのいずれかは、その5’末端が少なくとも1つのアクセプターフルオロフォアにより標識されている。)
d.前記標識されたLF又はLBループプライマーに対して5’の位置で前記標的核酸配列にハイブリダイズすることができ、その結果、核酸プローブが前記標的核酸配列にハイブリダイズした際に、前記標識されたLF又はLBループプライマーの前記5’末端に、前記核酸プローブの前記3’末端が近接している1つの核酸プローブからなり、
前記核酸プローブは、前記LF又はLBループプライマーの前記少なくとも1つのアクセプターフルオロフォアに励起エネルギーを伝達することができる少なくとも1つのドナーフルオロフォアにより、その3’末端が標識され、前記アクセプターフルオロフォアの蛍光発光の強度が前記ドナーフルオロフォア励起エネルギーの吸収時に増加する、上記オリゴヌクレオチドのセット。 - 前記少なくとも1つのドナーフルオロフォアが、フルオレセイン、BODIPY FL、Alexa555、ATTO550、Cy3、FAM、TET、HEX、JOE、VIC、Cy3、NED、Quasar 570、Oyster 556、TAMRA、Cy5.5、Cy5、ATTO647N、Alexa 647、ROX、LC red 610、Texas red、LC red 640、LC red 670、Quasar 670、Oyster 645、LC red 705からなる群から選択され、及び/又は前記少なくとも1つのアクセプターフルオロフォアが、Cy5.5、Cy5、ATTO647N、Alexa 647、ROX、LC red 610、Texas red、LC red 640、LC red 670、Quasar 670、Oyster 645、LC red 705からなる群から選択される、請求項6に記載のオリゴヌクレオチドのセット。
- 標的核酸配列のループ介在等温増幅(LAMP)を検出するためのキットであって、前記キットが、請求項6又は7に記載のオリゴヌクレオチドのセット及び鎖置換活性を有するDNAポリメラーゼを含む、キット。
- 前記DNAポリメラーゼが、Bstラージフラグメントポリメラーゼ、Bst2.0、Bst3.0、Bca(exo−)、Vent、Vent(exo−)、Deep Vent、Deep Vent(exo−)、Φ29ファージ、MS−2ファージ、Z−Taq、KOD、クレノウフラグメント、GspSSD、GspF、OmniAmp Polimerase、SD Polimerase及びそれらの任意の組合せからなる群から選択される、請求項8に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102015000086668 | 2015-12-22 | ||
ITUB2015A009332A ITUB20159332A1 (it) | 2015-12-22 | 2015-12-22 | Procedimento di rivelazione in fluorescenza dell?amplificazione isotermica mediata da loop (LAMP) di un acido nucleico bersaglio, relativi oligonucleotidi e kit. |
PCT/EP2016/081673 WO2017108663A1 (en) | 2015-12-22 | 2016-12-19 | A method of fluorescent detection of isothermal loop-mediated amplification (lamp) of a target nucleic acid, oligonucleotides and kits thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018537988A true JP2018537988A (ja) | 2018-12-27 |
JP7023229B2 JP7023229B2 (ja) | 2022-02-21 |
Family
ID=55795044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018532236A Active JP7023229B2 (ja) | 2015-12-22 | 2016-12-19 | 標的核酸のループ介在等温増幅(lamp)の蛍光検出の方法、オリゴヌクレオチド及びそれらのキット |
Country Status (8)
Country | Link |
---|---|
US (2) | US10982270B2 (ja) |
EP (1) | EP3394287B1 (ja) |
JP (1) | JP7023229B2 (ja) |
CN (1) | CN108431235A (ja) |
AU (1) | AU2016376478B2 (ja) |
ES (1) | ES2875276T3 (ja) |
IT (1) | ITUB20159332A1 (ja) |
WO (1) | WO2017108663A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITUB20159332A1 (it) | 2015-12-22 | 2017-06-22 | Diasorin S P A | Procedimento di rivelazione in fluorescenza dell?amplificazione isotermica mediata da loop (LAMP) di un acido nucleico bersaglio, relativi oligonucleotidi e kit. |
JP6584986B2 (ja) * | 2016-03-18 | 2019-10-02 | 株式会社東芝 | 核酸検出方法 |
GB201713251D0 (en) * | 2017-08-18 | 2017-10-04 | Lgc Genomics Ltd | Methods and kits for detection of nucleic acid molecules |
SG10201910254YA (en) * | 2019-11-04 | 2021-06-29 | Denka Company Ltd | Nucleic Acid Detection Method Using Lamp And Probe Detection |
CN111154820B (zh) * | 2020-01-13 | 2021-12-21 | 上海韦翰斯生物医药科技有限公司 | 一种降低核酸扩增复制滑移率的方法 |
CN112795629A (zh) * | 2020-02-14 | 2021-05-14 | 李治国 | 提高基因检测灵敏度和速度的方法 |
US11149320B1 (en) | 2020-03-31 | 2021-10-19 | Diasorin S.P.A. | Assays for the detection of SARS-CoV-2 |
CN115836133A (zh) | 2020-04-30 | 2023-03-21 | 萨达维达生物科学研究与服务有限公司 | 用于检测疑似冠状病毒样品中的核酸序列的方法和便携式装置 |
US20240327933A1 (en) * | 2020-12-16 | 2024-10-03 | The Broad Institute, Inc. | Coronavirus rapid diagnostics |
CN113201593B (zh) * | 2021-05-25 | 2024-01-23 | 广州盛世中豪运动科技有限公司 | 用于检测actn3基因型的引物探针组合产品 |
WO2023046658A1 (en) * | 2021-09-22 | 2023-03-30 | University College Cardiff Consultants Limited | Multiplex primers and method of use |
WO2023060006A2 (en) * | 2021-09-28 | 2023-04-13 | The Regents Of The University Of California | Methods and devices for using airflow-driven, evaporative gradients |
CN113846146B (zh) * | 2021-12-02 | 2022-02-18 | 上海众启生物科技有限公司 | 一种重叠环介导等温核酸扩增技术 |
KR20240104144A (ko) * | 2021-12-10 | 2024-07-04 | 주식회사 씨젠 | 단일 가닥 상호작용적 이중 표지 시스템을 포함하는 태그된 루프프라이머 및 이를 이용한 핵산 등온 증폭 방법 |
EP4453249A1 (en) * | 2021-12-24 | 2024-10-30 | F. Hoffmann-La Roche AG | Improved detection of lamp amplification products |
US20230366038A1 (en) * | 2022-05-16 | 2023-11-16 | Bioo Scientific Corporation | Compositions and methods relating to loop mediated isothermal amplification (lamp) |
CN116908265B (zh) * | 2023-09-11 | 2023-12-12 | 常州先趋医疗科技有限公司 | 检测核酸lamp扩增产物电化学生物传感器的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012239424A (ja) * | 2011-05-19 | 2012-12-10 | Sony Corp | 核酸塩基配列解析方法および核酸塩基配列解析のためのマイクロチップと混合試薬 |
WO2014157377A1 (ja) * | 2013-03-26 | 2014-10-02 | 株式会社ニッポンジーン | 遺伝子多型の識別に用いるプライマーとプローブのセットおよびその利用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009049630A1 (en) * | 2007-10-16 | 2009-04-23 | Aarhus Universitet | Isothermal amplification method for detection of nucleic acid mutation |
KR101832011B1 (ko) * | 2010-06-22 | 2018-02-23 | 유니버시티 오브 하와이 | 루프-매개 등온 증폭(lamp)의 서열 특이적 실시간 모니터링 |
US20170058366A1 (en) * | 2014-02-21 | 2017-03-02 | The United States of America, as represented by th e Secretary, Dept. of Health and Human Services | Hiv-2 nucleic acids and methods of detection |
US10724091B1 (en) * | 2015-02-10 | 2020-07-28 | National Technology & Engineering Solutions Of Sandia, Llc | Endpoint detection of amplified nucleic acids |
ITUB20159332A1 (it) * | 2015-12-22 | 2017-06-22 | Diasorin S P A | Procedimento di rivelazione in fluorescenza dell?amplificazione isotermica mediata da loop (LAMP) di un acido nucleico bersaglio, relativi oligonucleotidi e kit. |
-
2015
- 2015-12-22 IT ITUB2015A009332A patent/ITUB20159332A1/it unknown
-
2016
- 2016-12-19 AU AU2016376478A patent/AU2016376478B2/en active Active
- 2016-12-19 US US16/061,991 patent/US10982270B2/en active Active
- 2016-12-19 CN CN201680074861.1A patent/CN108431235A/zh active Pending
- 2016-12-19 JP JP2018532236A patent/JP7023229B2/ja active Active
- 2016-12-19 ES ES16823242T patent/ES2875276T3/es active Active
- 2016-12-19 EP EP16823242.9A patent/EP3394287B1/en active Active
- 2016-12-19 WO PCT/EP2016/081673 patent/WO2017108663A1/en active Application Filing
-
2021
- 2021-04-09 US US17/226,475 patent/US11827923B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012239424A (ja) * | 2011-05-19 | 2012-12-10 | Sony Corp | 核酸塩基配列解析方法および核酸塩基配列解析のためのマイクロチップと混合試薬 |
WO2014157377A1 (ja) * | 2013-03-26 | 2014-10-02 | 株式会社ニッポンジーン | 遺伝子多型の識別に用いるプライマーとプローブのセットおよびその利用 |
Non-Patent Citations (1)
Title |
---|
JOURNAL OF VIROLOGICAL METHODS, vol. 173, JPN6020046005, 2011, pages 67 - 74, ISSN: 0004552702 * |
Also Published As
Publication number | Publication date |
---|---|
US20180371534A1 (en) | 2018-12-27 |
AU2016376478B2 (en) | 2022-03-24 |
EP3394287A1 (en) | 2018-10-31 |
EP3394287B1 (en) | 2021-03-31 |
US20210230682A1 (en) | 2021-07-29 |
ES2875276T3 (es) | 2021-11-10 |
JP7023229B2 (ja) | 2022-02-21 |
WO2017108663A1 (en) | 2017-06-29 |
US11827923B2 (en) | 2023-11-28 |
US10982270B2 (en) | 2021-04-20 |
ITUB20159332A1 (it) | 2017-06-22 |
CN108431235A (zh) | 2018-08-21 |
AU2016376478A1 (en) | 2018-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11827923B2 (en) | Method of fluorescent detection of isothermal loop-mediated amplification (LAMP) of a target nucleic acid, oligonucleotides and kits thereof | |
US7972786B2 (en) | Detection and analysis of influenza virus | |
US9809846B2 (en) | Compositions, kits, uses and methods for amplified detection of an analyte | |
US9328377B2 (en) | Detection of target nucleic acid using a target hybridization and detection primer | |
JP6638122B2 (ja) | 標的核酸の検出方法及びキット | |
JP2004511227A (ja) | 核酸の同種内検出用の特異的二本鎖プローブおよびその適用方法 | |
KR20120107488A (ko) | Tsg프라이머 타겟 검출 | |
WO2015147370A1 (en) | Detection of target nucleic acid sequences using different detection temperatures | |
EP3055430B1 (en) | Method for the detection of target nucleic acid sequences | |
RU2595420C2 (ru) | Композиции, способы и наборы для гибридизации нуклеиновой кислоты | |
Yang et al. | An amplification-free detection method of nucleic acids by a molecular beacon probe based on endonuclease activity | |
US20130210001A1 (en) | Sequence detection assay | |
US20210189473A1 (en) | Universal tail primers with multiple binding motifs for multiplexed detection of single nucleotide polymorphisms | |
JP2012503472A (ja) | 診断用ハイブリダイゼーションアッセイにおける核酸標的の配列変異に対する依存性を低下させるための方法 | |
US20240352508A1 (en) | Methods, systems and compositions for detection of multiple analytes | |
WO2024015999A1 (en) | Methods, systems and compositions for detection of multiple analytes | |
KR20230091008A (ko) | 고리매개 등온 증폭용 변형된 프라이머 및 이의 용도 | |
RU2631615C2 (ru) | Способ и набор реагентов для выявления полиморфизмов в генах LINGO1, LINGO2 и SLC1A2, определяющих генетическую ассоциацию с эссенциальным тремором | |
WO2024017763A1 (en) | Method for nucleic acid detection using signal-mediated amplification of rna technology and rna aptamers | |
AU2022395070A1 (en) | Improved isothermal amplification |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191204 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210222 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210720 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211118 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20211118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20211118 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20211213 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20211214 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220119 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220208 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7023229 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |